David W Cescon - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

David W Cescon

Showing results (21-30 of 133) with videos related to

Pageof 14

Sort By:

Frontiers in Genetics|April 17, 2023

Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potentialBrooke E Wilson, Qiang Shen, David W Cescon, et al.

Cancer Treatment Reviews|September 4, 2018

Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapyIbrahim Algorashi, Hadar Goldvaser, Domen Ribnikar, et al.

Nature Cancer|February 5, 2022

Circulating tumor DNA and liquid biopsy in oncologyDavid W Cescon, Scott V Bratman, Steven M Chan, et al.

Bioorganic & Medicinal Chemistry Letters|February 14, 2018

Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerizationAdam Siddiqui-Jain, Jacob P Hoj, David W Cescon, et al.

Advanced Healthcare Materials|December 12, 2025

A Biomimetic Buffering Hydrogel Scaffold for Long-Term Culture of Patient-Derived Tumor OrganoidsElizaveta Gusarova, Fatemeh Ahmadi, Jennifer Cruickshank, et al.

Radiation Oncology (London, England)|February 16, 2024

PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancerSierra Pellizzari, Vasudeva Bhat, Harjot Athwal, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008

Evolution of the randomized controlled trial in oncology over three decadesChristopher M Booth, David W Cescon, Lisa Wang, et al.

Breast (Edinburgh, Scotland)|April 18, 2021

Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancerArmen Parsyan, Jennifer Cruickshank, Kelsey Hodgson, et al.

Breast Cancer Research and Treatment|February 10, 2018

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysisHadar Goldvaser, Habeeb Majeed, Domen Ribnikar, et al.

Breast Cancer Research and Treatment|June 19, 2012

Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancerDavid W Cescon, Patricia A Ganz, Samantha Beddows, et al.

Pageof 14

Search research articles

Showing results (21-30 of 133) with videos related to

Sort By:

Pageof 14

Frontiers in Genetics|April 17, 2023

Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potentialBrooke E Wilson, Qiang Shen, David W Cescon, et al.

Cancer Treatment Reviews|September 4, 2018

Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapyIbrahim Algorashi, Hadar Goldvaser, Domen Ribnikar, et al.

Nature Cancer|February 5, 2022

Circulating tumor DNA and liquid biopsy in oncologyDavid W Cescon, Scott V Bratman, Steven M Chan, et al.

Bioorganic & Medicinal Chemistry Letters|February 14, 2018

Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerizationAdam Siddiqui-Jain, Jacob P Hoj, David W Cescon, et al.

Advanced Healthcare Materials|December 12, 2025

A Biomimetic Buffering Hydrogel Scaffold for Long-Term Culture of Patient-Derived Tumor OrganoidsElizaveta Gusarova, Fatemeh Ahmadi, Jennifer Cruickshank, et al.

Radiation Oncology (London, England)|February 16, 2024

PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancerSierra Pellizzari, Vasudeva Bhat, Harjot Athwal, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008

Evolution of the randomized controlled trial in oncology over three decadesChristopher M Booth, David W Cescon, Lisa Wang, et al.

Breast (Edinburgh, Scotland)|April 18, 2021

Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancerArmen Parsyan, Jennifer Cruickshank, Kelsey Hodgson, et al.

Breast Cancer Research and Treatment|February 10, 2018

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysisHadar Goldvaser, Habeeb Majeed, Domen Ribnikar, et al.

Breast Cancer Research and Treatment|June 19, 2012

Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancerDavid W Cescon, Patricia A Ganz, Samantha Beddows, et al.

Pageof 14